Pol Polyprotein - Pipeline Review, H1 2016

  • ID: 3802742
  • Report
  • 52 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GeoVax Labs, Inc.
  • Johnson & Johnson
  • MORE
Pol Polyprotein - Pipeline Review, H1 2016

Summary

‘Pol Polyprotein - Pipeline Review, H1 2016’, provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics.

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein
- The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects
- The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Pol Polyprotein
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pol Polyprotein development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GeoVax Labs, Inc.
  • Johnson & Johnson
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Pol Polyprotein Overview

Therapeutics Development

Pol Polyprotein - Products under Development by Stage of Development

Pol Polyprotein - Products under Development by Therapy Area

Pol Polyprotein - Products under Development by Indication

Pol Polyprotein - Pipeline Products Glance

Late Stage Products

Early Stage Products

Pol Polyprotein - Products under Development by Companies

Pol Polyprotein - Products under Development by Universities/Institutes

Pol Polyprotein - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Route of Administration

Assessment by Molecule Type

Pol Polyprotein - Companies Involved in Therapeutics Development

GeoVax Labs, Inc.

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Pol Polyprotein - Drug Profiles

GOVXB-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GOVXC-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GOVXC-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV [serotype Ad26] (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV-1 (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV-1 vaccine 11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV-1 vaccine 5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PENNVAX-B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PENNVAX-GP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pol Polyprotein - Dormant Projects

Pol Polyprotein - Featured News & Press Releases

May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11

Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant

Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates

Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine

Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine

Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress

Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program

Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases

Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV

Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data

Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health

Jan 23, 2014: GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases

Jan 13, 2014: GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients

Oct 09, 2013: GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV

Jan 10, 2013: GeoVax Announces Enrollment Completion For Phase I/II Clinical Trial For HIV/AIDS Therapeutic Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 52List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by GeoVax Labs, Inc., H1 2016

Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

Pipeline by Johnson & Johnson, H1 2016

Dormant Projects, H1 2016 38List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • GeoVax Labs, Inc.
  • Johnson & Johnson
  • MORE
Pol Polyprotein pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Pol Polyprotein - Pipeline Review, H1 2016, outlays comprehensive information on the Pol Polyprotein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Pol Polyprotein Pol polyprotein belong to a class of viral structural proteins. It cleaves in to three chains protease, reverse transcriptase and integrase. During replicative cycle of retroviruses, the reverse-transcribed viral DNA is integrated into the host chromosome by the viral integrase enzyme. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Pol Polyprotein targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
GeoVax Labs, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll